Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract

Inflamm Bowel Dis. 2001 May;7(2):99-105. doi: 10.1097/00054725-200105000-00004.


Background: To follow-up clinical and biochemical features in patients with Crohn's disease (CD) of the upper gastrointestinal (GI) tract and to evaluate the impact of different therapeutics on the outcome of these patients.

Methods: 32 CD patients with endoscopically and histologically proven CD of the upper GI tract were included into this retrospective study. Gastroduodenal and intestinal permeability tests, inflammatory parameters, Crohn's Disease Activity Index (CDAI), and upper gastrointestinal complaint profile were sequentially assessed. These parameters were assessed at the beginning and followed up during therapies with antisecretory drugs, mesalamine, prednisolone, and azathioprine.

Results: Symptoms responded to antisecretory drugs. Gastroduodenal permeability increased under mesalamine. Gastroduodenal and intestinal permeability as well as CDAI decreased under prednisolone. Under azathioprine, gastroduodenal and intestinal permeability, CDAI, and C-reactive protein decreased.

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Anti-Ulcer Agents / therapeutic use*
  • Crohn Disease / drug therapy*
  • Crohn Disease / metabolism
  • Data Interpretation, Statistical
  • Disaccharides
  • Duodenal Diseases / drug therapy*
  • Esophageal Diseases / drug therapy*
  • Famotidine / therapeutic use
  • Female
  • Humans
  • Lansoprazole
  • Male
  • Mannitol
  • Mesalamine / therapeutic use
  • Middle Aged
  • Omeprazole / analogs & derivatives
  • Omeprazole / therapeutic use*
  • Permeability
  • Proton Pumps / therapeutic use
  • Retrospective Studies
  • Stomach Diseases / drug therapy*
  • Treatment Outcome


  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Disaccharides
  • Proton Pumps
  • Lansoprazole
  • Mannitol
  • Mesalamine
  • Famotidine
  • Omeprazole